[Federal Register: July 19, 1999 (Volume 64, Number 137)]
[Notices]               
[Page 38689-38690]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19jy99-112]                         

-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 731-TA-828 (Preliminary)]

 
Bulk Acetylsalicylic Acid (Aspirin) From China

Determination

    On the basis of the record <SUP>1</SUP> developed in the subject 
investigation, the United States International Trade Commission 
determines, pursuant to section 733(a) of the Tariff Act of 1930 (19 
U.S.C. 1673b(a)), that there is a reasonable indication that an 
industry in the United States is threatened with material injury by 
reason of imports from China of bulk acetylsalicylic acid (aspirin), 
provided for in subheadings 2918.22.10 and 3003.90.00 of the Harmonized 
Tariff Schedule of the United States, that are alleged to be sold in 
the United States at less than fair value (LTFV). <SUP>2</SUP>
---------------------------------------------------------------------------

    \1\ The record is defined in Sec. 207.2(f) of the Commission's 
rules of practice and procedure (19 CFR 207.2(f)).
    \2\ Commissioner Carol T. Crawford determines that there is a 
reasonable indication that an industry in the United States is 
materially injured by reason of the subject imports from China that 
are alleged to be sold in the United States at LTFV.
---------------------------------------------------------------------------

Commencement of Final Phase Investigation

    Pursuant to section 207.18 of the Commission's rules, the 
Commission also gives notice of the commencement of the final phase of 
its investigation. The Commission will issue a final phase notice of 
scheduling which will be published in the Federal Register as provided 
in Sec. 207.21 of the Commission's rules upon notice from the 
Department of Commerce (Commerce) of an affirmative preliminary 
determination in the investigation under section 733(b) of the Act, or, 
if the preliminary determination is negative, upon notice of an 
affirmative final determination in that investigation under section 
735(a) of the Act. Parties that filed entries of appearance in the 
preliminary phase of the investigation need not enter a separate 
appearance for the final phase of the investigation. Industrial users, 
and, if the merchandise under investigation is sold at the retail 
level, representative consumer organizations have the right to appear 
as parties in Commission antidumping and countervailing duty 
investigations. The Secretary will prepare a public service list 
containing the names and addresses of all persons, or their 
representatives, who are parties to the investigation.

[[Page 38690]]

Background

    On May 28, 1999, a petition was filed with the Commission and the 
Department of Commerce by Rhodia, Inc., Cranbury, NJ, alleging that an 
industry in the United States is materially injured or threatened with 
material injury by reason of LTFV imports of bulk aspirin from China. 
Accordingly, effective May 28, 1999, the Commission instituted 
antidumping investigation No. 731-TA-828 (Preliminary).
    Notice of the institution of the Commission's investigation and of 
a public conference to be held in connection therewith was given by 
posting copies of the notice in the Office of the Secretary, U.S. 
International Trade Commission, Washington, DC, and by publishing the 
notice in the Federal Register of June 7, 1999 (64 FR 30355). The 
conference was held in Washington, DC, on June 18, 1999, and all 
persons who requested the opportunity were permitted to appear in 
person or by counsel.
    The Commission transmitted its determination in this investigation 
to the Secretary of Commerce on July 12, 1999. The views of the 
Commission are contained in USITC Publication 3211 (July 1999), 
entitled Bulk Acetylsalicylic Acid (Aspirin) from China: Investigation 
No. 731-TA-828 (Preliminary).

    By order of the Commission.
    Issued: July 13, 1999.
Donna R. Koehnke,
Secretary.
[FR Doc. 99-18335 Filed 7-16-99; 8:45 am]
BILLING CODE 7020-02-P